Chop Versus Gem‐p in the First‐line Treatment of T‐cell Lymphoma (Ptcl): Initial Results of the Uk Nrci Phase Ii Randomised Chemo‐t Trial

Abstract

and their diagnosis is often challenging for pathologists. Up to 30% of cases thus remain not classifiable (PTCL Not Otherwise Specified, NOS) and there is an important need for alternative diagnostic strategies. Here, we developed a parsimonious GEP assay applicable to a routine diagnostic workflow to differentiate the main PTCL entities and characterize the heterogeneity of PTCL-NOS. This study demonstrates the applicability of a robust RT-MLPA classifier for the classification of PTCLs. Its simplicity and its applicability on FFPE samples makes it an attractive alternative to high throughout GEP approaches. In combination with conventional pathological evaluation and IHC, it may participate to improve the classification of PTCLs and the management of these aggressive tumors.

Recent advances in understanding and managing T-cell lymphoma

“…The CR rate was 67%, and the five-year event-free survival rate was 49%. In a recent report from the randomized phase II study of the UK group using the combination of gemcitabine, cisplatin, and methylprednisolone (GEM-P), objective response rates (ORRs) were 57.1% for the CHOP arm and 43.2% for the experimental arm 37 . Although grade 3–4 neutropenia or febrile neutropenia was more common in the CHOP arm, there was no difference in the two-year OS rate (53.1% versus 64.7%) or PFS rate (36.0% versus 39.0%).…”

Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission

“…While the majority of patients with aggressive lymphomas achieve complete remission (CR) with anthracycline-based combination chemotherapy, up to 50% of patients will relapse. 1–3 As a significant proportion of patients who relapse are considered for salvage chemotherapy and curative-intent autologous stem cell transplant, surveillance after first-line therapy is recommended. 4…”